Cochrane · systematic review · CD011044
Chemotherapy and radiotherapy for advanced pancreatic cancer
Chin, V, Nagrial, A, Sjoquist, K, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 28.6%Moderate 6 · 42.9%High 4 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐cancer therapy versus best supportive care for advanced pancreatic cancer
Population: advanced pancreatic cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Anti‐cancer therapy vs best supportive care | HR 1.08 [0.88, 1.33] | 4 studies · 298 participants | Moderate Downgraded: imprecision |
Various types of chemotherapy versus gemcitabine for advanced pancreatic cancer
Population: advanced pancreatic cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ 5FU Various types of chemotherapy vs gemcitabine | HR 1.69 [1.26, 2.27] | 1 study · 126 participants | Moderate Downgraded: imprecision |
Overall survival ‐ FOLFIRINOX Various types of chemotherapy vs gemcitabine | HR 0.51 [0.43, 0.6] | 2 studies · 652 participants | Moderate Downgraded: inconsistency |
Overall survival ‐ Fixed dose rate gemcitabine Various types of chemotherapy vs gemcitabine | HR 0.79 [0.66, 0.94] | 2 studies · 644 participants | High |
Overall survival ‐ CO‐101 Various types of chemotherapy vs gemcitabine | HR 1.07 [0.86, 1.34] | 1 study · 367 participants | Moderate |
Overall survival ‐ ZD9331 Various types of chemotherapy vs gemcitabine | HR 0.86 [0.42, 1.76] | 1 study · 55 participants | Moderate Downgraded: imprecision |
Overall survival ‐ Exatecan Various types of chemotherapy vs gemcitabine | HR 1.27 [0.96, 1.68] | 1 study · 339 participants | Moderate |
Gemcitabine combinations versus gemcitabine alone for advanced pancreatic cancer
Population: advanced pancreatic cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ Gemcitabine plus platinum agent Gemcitabine combinations vs gemcitabine alone | HR 0.94 [0.81, 1.08] | 6 studies · 1140 participants | Low |
Overall survival ‐ Gemcitabine plus fluoropyrimidine Gemcitabine combinations vs gemcitabine alone | HR 0.89 [0.81, 0.97] | 10 studies · 2718 participants | High |
Overall survival ‐ Gemcitabine plus topoisomerase inhibitor Gemcitabine combinations vs gemcitabine alone | HR 1.01 [0.87, 1.16] | 3 studies · 839 participants | High |
Overall survival ‐ Gemcitabine plus taxane Gemcitabine combinations vs gemcitabine alone | HR 0.72 [0.62, 0.84] | 1 study · 861 participants | High |
Overall survival ‐ Gemcitabine plus other combinations of chemotherapy Gemcitabine combinations vs gemcitabine alone | HR 0.55 [0.39, 0.79] | 2 studies · 166 participants | Low Downgraded: imprecision, inconsistency |
Overall survival ‐ Gemcitabine plus other agent(s) Gemcitabine combinations vs gemcitabine alone | HR 0.79 [0.56, 1.1] | 4 studies · 767 participants | Low Downgraded: inconsistency |
Fluoropyrimidine combinations versus fluoropyrimidine alone for advanced pancreatic cancer
Population: advanced pancreatic cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Fluoropyrimidine combinations vs fluoropyrimidine alone | HR 0.84 [0.61, 1.15] | 4 studies · 491 participants | Low Downgraded: inconsistency |